Date: 2015-03-30
Type of information: Licensing agreement
Compound: aviptadil
Company: Therametrics (Switzerland) Centurion Pharma (Turkey)
Therapeutic area: Inflammatory diseases
Type agreement: licensing collaboration
Action mechanism:
Disease: sarcoidosis
Details: * On March 30 2015, Therametrics and Centurion Pharma announced that they have signed a final licensing agreement for aviptadil, Therametrics’ drug candidate for sarcoidosis. Both parties signed a term sheet for this agreement in August 2014. The two companies will cooperate in the development and registration of aviptadil for the treatment of sarcoidosis in Turkey and in other neighbouring markets. At the same time, both companies have signed Letters of Intent for contract research services for: * On August 4, 2014, TheraMetrics announced that it has signed a Term Sheet with Centurion Pharma, a leading Turkish International R&D based company active in the rare diseases field. Under the proposed terms the two companies will cooperate in the development and registration of aviptadil for the treatment of cystic fibrosis and sarcoidosis and interferon gamma for the treatment of idiopathic pulmonary fibrosis. The Term Sheet outlines the terms for the collaboration in Turkey and eventually in other neighbouring markets. TheraMetrics is the patent holder on both products in the given indications (cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis) and has adopted Orphan Medicinal Product Designations in the USA and Europe. The Parties have committed to sign definitive agreements by December 2014.
- development of aviptadil in sarcoidosis in Turkey including design, organization and execution of the clinical development plan for the registration of aviptadil in Turkey;
- future development of aviptadil in additional geographical regions;
- joint Research and Development on different projects employing Therametrics’ DRR2.0 Drug Repositioning technology.
Financial terms:
Latest news:
